Suratadenoturev

舒拉艾若

Report date: 2024/05/17 12:02:49

Base Information

Drug NameSuratadenoturev
Drug Alias NameTelomerase-specific Type 5 Adenovirus OBP-301 (Oncolys Biopharma)TelomelysinOBP-301
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionTelomerase inhibitors
TargetsTelomerase
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanSouth Korea +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncolys Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell UniversityOncolys Biopharma IncNational Cancer Institute +[4] 
Inactive CompaniesChugai Pharmaceutical Co Ltd
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[9] 
Inactive IndicationsSquamous Cell Carcinoma of Head and NeckMelanoma

Other Information

ATC CodeN/A
Related LinksN/A